Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

由此可见，mRNA-4157（V940）联合帕博利珠单抗在黑色素瘤患者中耐受性良好。 而mRNA-4157（V940）预计最早在2025年上市，这将会是全球首款mRNA肿瘤疫苗。

2024年9月13日-17日，欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那召开，作为肿瘤内科最高规模的国际盛会，涉及肺癌、乳腺癌、消化道肿瘤、泌尿生殖系统肿瘤等领域的多项研究届时皆将披露最新进展。

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...

周一，Summit Therapeutics (SMMT.US)股价一路暴涨。截至发稿，该股涨幅达55.99%，报19.14美元。这是自2017年9月11日收于16.00美元以来的首次创纪录收盘新高，而且，今年迄今为止增长了632.38％。

在初步分析中，与单一疗法pembrolizumab相比，ivonescimab单药治疗在试验的主要终点无进展生存期方面表现出统计学上显着改善，从而成为在 NSCLC 随机后期临床试验中第一个比pembrolizumab获得临床意义益处的药物。

Piper Sandler维持对Gilead Sciences (NASDAQ: GILD)的"增持"评级，目标价为95.00美元。 该公司的分析是在世界肺癌大会 (WCLC)关于各种TROP2靶向ADC项目（包括Gilead Sciences的项目 ...